BEIJING, Dec. 1, 2017 /PRNewswire/ -- Sinovac Biotech Ltd.
(Nasdaq: SVA) (the "Company" or "Sinovac"), a leading provider of
biopharmaceutical products in China, announced today that it has received a
Nasdaq Staff letter indicating that the Form 20-F filing
delinquency, which was the subject of a prior Nasdaq Staff
Determination letter, has been cured after the Company filed its
annual report on Form 20-F for the year ended December 31, 2016 with the SEC on November 22, 2017. In the letter, Nasdaq
indicated that the Company is in compliance with all applicable
listing standards. As a result, the previously scheduled
delisting hearing with the Nasdaq Listing Qualifications Panel has
been canceled.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacturing and
commercialization of vaccines that protect against human infectious
diseases. Sinovac's product portfolio includes vaccines against
enterovirus71, or EV71, hepatitis A and B, seasonal influenza, H5N1
pandemic influenza (avian flu), H1N1 influenza (swine flu), and
mumps. The EV71 vaccine, an innovative vaccine developed by Sinovac
against hand foot and mouth disease caused by EV71, was
commercialized in China in 2016.
In 2009, Sinovac was the first company worldwide to receive
approval for its H1N1 influenza vaccine, which it has supplied to
the Chinese Government's vaccination campaign and stockpiling
program. The Company is also the only supplier of the H5N1 pandemic
influenza vaccine to the government stockpiling program. The
Company is developing a number of new products including a
Sabin-strain inactivated polio vaccine, pneumococcal
polysaccharides vaccine, pneumococcal conjugate vaccine and
varicella vaccine. Sinovac primarily sells its vaccines in
China, while also exploring growth
opportunities in international markets. The Company has exported
select vaccines to over 10 countries in Asia and South America. For more
information, please visit the Company's website at
www.sinovac.com.
Safe Harbor Statement
This announcement may include certain statements that are not
descriptions of historical facts, but are forward-looking
statements. These statements are made under the "safe harbor"
provisions of the U.S. Private Securities Litigation Reform Act of
1995. These forward-looking statements can be identified by
terminology such as "will," "expects," "anticipates," "future,"
"intends," "plans," "believes," "estimates" and similar statements.
Forward-looking statements involve risks, uncertainties and other
factors that could cause actual results to differ materially from
those contained in any such statements.
Contact
Sinovac Biotech Ltd.
Helen
Yang
Tel: +86-10-8279-9871
Fax: +86-10-6296-6910
Email: ir@sinovac.com
ICR Inc.
Bill Zima
U.S: 1-646-308-1707
Email: william.zima@icrinc.com
View original
content:http://www.prnewswire.com/news-releases/sinovac-biotech-cures-nasdaq-filing-deficiency-300565032.html
SOURCE Sinovac Biotech Ltd.